This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pfizer Children's Vaccine Receives European OK

NEW YORK (AP) ¿ Pfizer Inc. said Friday European regulators have approved a new version of its children's pneumococcal vaccine, Prevenar 13.

The vaccine is approved for children aged 6 weeks to 5 years to prevent pneumococcal disease, as well as pneumonia and middle ear infections caused by related strains of the bacterium. Pneumococcal disease can also cause meningitis and blood infections.

The European Commission's approval was based on late-stage clinical studies of more than 7,000 children that showed the drug's safety and effectiveness, Pfizer said in a statement.

The drug was developed by Wyeth. New York-based Pfizer, the world's largest drugmaker, bought Wyeth for $68 billion in a deal completed earlier this year. Wyeth said in September that European Union regulators had recommended approval of Prevenar 13.

The original vaccine, Prevenar, was Wyeth's second best-selling drug, with $2.7 billion in revenue in 2008 as the world's best-selling vaccine. The original version blocks seven strains of pneumococcal bacteria. The new version blocks a total of 13 strains.

The vaccine is still being reviewed by the U.S. Food and Drug Administration.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PFE $32.62 -0.87%
AAPL $93.61 -1.30%
FB $116.48 -0.21%
GOOG $692.54 0.22%
YHOO $36.35 -0.66%


Chart of I:DJI
DOW 17,729.30 -101.46 -0.57%
S&P 500 2,059.25 -16.56 -0.80%
NASDAQ 4,762.78 -42.5110 -0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs